Thomas Goddard

Thomas Goddard

Auto-generated profile, based on publicly available information

Thomas Goddard

Department of Respiratory and Sleep Medicine, Women’s and Children’s Hospital

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
MAMorgan Atkinson
Morgan Atkinson
AMAndrew Murnane
Andrew Murnane
TGThomas Goddard
Thomas Goddard
CPCathy Pendergrast
Cathy Pendergrast
PRPaul Rogers
Paul Rogers
MOMichael Osborn
Michael Osborn

1 September 2016 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
GSGianny P. Scoleri
Gianny P. Scoleri
JCJocelyn M. Choo
Jocelyn M. Choo
Lex LeongLex Leong
Lex Leong
TGThomas R. Goddard
Thomas R. Goddard
LSLisa Shephard
Lisa Shephard
GRGeraint B. Rogers
Geraint B. Rogers
Culture-based detection of nontuberculous Mycobacteria (NTM) in respiratory samples is time consuming and can be subject to overgrowth by nonmycobacterial bacteria. We describe a single-reaction TaqMan quantitative PCR assay for the direct detection of NTM species in clinical samples that is specific, sensitive, and robust.

6 January 2017 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
TGThomas Goddard
Thomas Goddard
CAChad Andersen
Chad Andersen
ATAndrew Tai
Andrew Tai
Extreme premature infants with cystic fibrosis typically do not survive the neonatal phase. This case report describes the youngest survivor of a premature infant with cystic fibrosis and highlights the importance of advanced neonatal care with cystic fibrosis therapy.

4 October 2022 in Australian Prescriber
Verified
Journal Article
Open access
MBMatthew Bruorton
Matthew Bruorton
TGThomas Goddard
Thomas Goddard
The life expectancy of patients with cystic fibrosis has improved so much, they are now experiencing chronic health conditions such as cardiovascular disease.

2 January 2026 in medRxiv
Verified
Preprint
Open access
PDF file
TGThomas R. Goddard
Thomas R. Goddard
JCJessica Ap. Carlson-Jones
Jessica Ap. Carlson-Jones
JMJudith Morton
Judith Morton
KOKeith Ooi
Keith Ooi
ATAndrew Tai
Andrew Tai
RERobert Edwards
Robert Edwards
Chronic infections in cystic fibrosis (CF) emerge from gradual ecological transitions in the airway microbiome, yet early predictive markers remain poorly defined. We developed a new autoencoder-based framework that outperforms read-based or metagenome-assembled genome-based analyses at capturing the continuum from health-associated commensals to pathogen-dominated, antibiotic-tolerant communities. This improvement is achieved by integrating taxonomic and functional data from 127 sputum and bronchoalveolar lavage metagenomes from 64 people with CF into latent “Clusters of Phylogeny and Functions” (COPFs). Coupled with gradient-boosted random forests, COPFs predicted Pseudomonas aeruginosa colonisation, multidrug resistance, and impending infection up to a year before clinical detection. The multidrug-resistant P. aeruginosa signature showed the same resistance-mechanism evolution as found in laboratory experiments. The inclusion of eukaryotic markers revealed persistent Aspergillus fumigatus signatures even during culture-negative intervals. Applying our South Australian-trained model to over 1,000 global metagenomes from 22 independent CF datasets, we achieved 94% accuracy in predicting P. aeruginosa status across platforms and geographies, validating the model’s universal utility. Our results demonstrate that combining datasets with deep learning reveals conserved ecological and metabolic mechanisms in disease progression, transforming metagenomics into a predictive framework for managing chronic infections.

10 September 2026 in Clinical Microbiology Reviews
Verified
Journal Article
Open access
JCJessica A. P. Carlson-Jones
Jessica A. P. Carlson-Jones
TGThomas R. Goddard
Thomas R. Goddard
BPBhavya Nalagampalli Papudeshi
Bhavya Nalagampalli Papudeshi
VMVijini Mallawaarachchi
Vijini Mallawaarachchi
KWKatrine L. Whiteson
Katrine L. Whiteson
RERobert Edwards
Robert Edwards
SUMMARY: DNA sequencing has revolutionized microbial surveillance in cystic fibrosis (CF), transforming pathogen identification from culture-dependent to total microbial community identification using molecular-based approaches. Techniques such as 16S rRNA gene sequencing have uncovered the complexity of the CF airway microbiome, while shotgun metagenomics, metatranscriptomics, and viromics now provide strain-level, functional, and viral insights beyond bacterial identification. Despite these advances, key technical and logistical challenges remain, including the processing of high-viscosity sputum samples, overwhelming host DNA contamination, managing large data sets, and the integration of complex bioinformatic outputs into clinical workflows. Emerging innovations such as host DNA depletion protocols, targeted enrichment panels, and adaptive sampling on Oxford Nanopore platforms are helping to overcome these barriers, improving microbial recovery and sequencing efficiency. As cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies are changing the lives of people with cystic fibrosis (pwCF), sequencing offers an unprecedented opportunity to track potential microbial adaptation in response. This review investigates current advances, limitations, and translational opportunities in DNA sequencing for CF airway microbiome surveillance, highlighting how these technologies can help reshape research and clinical microbiology in the post-modulator era.